| Investor Relations HomeHere you will find financial reports and shareholder information about Omeros Corporation, including recent news, current and historical share price, and electronic copies of our SEC filings. | | |
| Recent Press Releases | More >> |
| Date | Title | | | | 01/10/12 | Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs| --Five Additional Orphans Unlocked by Omeros Linked to Liver Cancer, Cognitive Impairments, Cardiovascular and Inflammatory Disorders--
SEATTLE, Jan. 10, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported that it has identified compounds that interact selectively with each of GPR25, GPR32, GPR80, GPR135 and MAS1, bringing the total number of orphan G protein-coupled receptors (GPCRs) unlocked by Omeros to 23, representing 30 percent of the Class A orphan GPCRs. To date, the... |
| |  | | 11/30/11 | Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs| Four Additional Orphans Unlocked by Omeros Linked to Melanoma, Anxiety, Gastrointestinal Disorders and Respiratory and Immune Disorders--
SEATTLE, Nov. 30, 2011 /PRNewswire via COMTEX/ --Omeros Corporation (NASDAQ: OMER) today reported that with its identification of compounds that interact selectively with each of four additional orphan G protein-coupled receptors (GPCRs) - GPR19, GPR20, GPR31 and GPR141 - it has now unlocked over 20 percent of the 77 Class A orphans. GPCRs represent the pr... |
| | | | 11/29/11 | Omeros Announces Submission to European Medicines Agency of Paediatric Investigation Plan Letter of Intent for OMS302|
SEATTLE, Nov. 29, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has submitted to the European Medicines Agency (EMA) a letter of intent to file its Paediatric Investigation Plan (PIP) for OMS302, the Company's product candidate for use during intra-ocular lens replacement surgery. A PIP is part of the EMA approval process and must be agreed prior to submission of a Marketing Authorization Application (MAA) for the drug in the European Union, unless... |
| | | | 11/22/11 | Omeros to Present at 23rd Annual Piper Jaffray Health Care Conference|
SEATTLE, Nov. 22, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the 23rd Annual Piper Jaffray Health Care Conference taking place in New York City next week. The presen... |
| | |
|
 |
|
| Date | Title | | 09/13/11 2:00 p.m. ET | |
|
Receive E-mail Alerts | | Sign up to receive e-mail alerts whenever Omeros Corporation posts new information to the site. Just enter your e-mail address and click Submit. |
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
|
